Form 4: BioCardia CEO Peter Altman Increases Stake in BCDA

BioCardia, Inc. President and CEO Peter Altman purchased 5,000 shares of common stock at $1.11 per share.

Summary

• Peter Altman, President and CEO of BioCardia, Inc., acquired 5,000 shares of common stock.
• The transaction occurred on April 29, 2026, at a price of $1.11 per share.
• Following this transaction, Mr. Altman's total beneficial ownership of common stock increased to 280,766 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects direct financial commitment from the CEO to the company's equity.

Positives

• Insider confidence is demonstrated by the CEO's decision to purchase additional shares with personal capital.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a CEO, is generally viewed by the market as a positive signal of management's belief in the company's long-term valuation and strategic direction.

Comparison to Industry Standards

• Insider purchases are a standard practice for executives to align their interests with shareholders.
• The volume of the purchase is relatively small compared to total outstanding shares, which is typical for routine insider activity.

Stakeholder Impact

• Shareholders may interpret this as a sign of management confidence in the company's future prospects.

Key Dates

Keywords

BioCardia, BCDA, Insider Trading, Form 4, Biotech, Stock Purchase